

NeuroNEXT Network

Standard Operating Procedure (SOP)





Communication

Version 2.0

SOP NN PM 501

Originators: NeuroNEXT CCC and DCC Personnel

Reviewed and Approved by:

Signature and Date: <small>DocuSigned by Christopher Coffey</small>  I approve this document 15-Feb-2023 8:19:46 AM PST <small>C68AC8DD80334CF982AED1200765F147</small>	15-Feb-2023
Name and Title: Christopher S. Coffey, PhD (DCC Principal Investigator)	
Signature and Date: <small>DocuSigned by Merit Cudkowicz</small>  I approve this document 17-Feb-2023 9:36:02 AM EST <small>9F8FE4180E504C6AB0A67B835E80C644</small>	17-Feb-2023
Name and Title: Merit E. Cudkowicz, MD MSc (CCC Principal Investigator)	
Signature and Date: <small>DocuSigned by Marianne Chase</small>  I approve this document 15-Feb-2023 8:49:08 PM EST <small>58FE690F6BCA4F2390E3DA15BCE3F578</small>	15-Feb-2023
Name and Title: Marianne Chase, BA (CCC Senior Director of Clinical Trials Operations)	
Signature and Date: <small>DocuSigned by DIXIE ECKLUND</small>  I approve this document 15-Feb-2023 11:05:15 AM PST <small>7006AF622EFC40B6A067A08EC02591B6</small>	15-Feb-2023

Name and Title: Dixie J. Ecklund, RN MSN MBA (DCC Associate Director)

Signature and Date:

DocuSigned by Stacey Grabert



Stacey Grabert

I approve this document
22-Feb-2023 | 11:24:16 AM EST

22-Feb-2023

60CC52B0747A44E6B2208D8D880698C0

Name and Title: Stacey Grabert, Pharm.D, MS, (CCC Director of Quality Assurance)

Signature and Date:

DocuSigned by Joan Ohayon



Joan Ohayon

I approve this document
15-Feb-2023 | 9:04:05 AM PST

15-Feb-2023

72C6AAFD8CC4485582ACA0700072901A

Name and Title: Joan Ohayon, RN, MSN, CRNP, MSCN (NINDS, NeuroNEXT Program Official)

NN PM 501

NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR COMMUNICATION

1. POLICY

Ongoing communications within the NeuroNEXT Network, including those between the National Institute of Neurological Diseases and Stroke (NINDS), the Clinical Coordinating Center (CCC), the Data Coordinating Center (DCC), the Clinical Study Sites (CSS), Protocol Principal Investigators (PPI), and all other relevant parties, is crucial to ensure the quality of all Network activities. By keeping all affected parties fully apprised of Network and study specific activities, accurate records of activities can be maintained and deviations from accepted procedures can be prevented. All communications should be appropriately detailed, documented on the appropriate forms or as meeting minutes, and distributed and/or filed as required by policy and/or regulation.

All pertinent Network and Study specific communications will be documented. Pertinent communications include, but may not be limited to, the following: scheduled teleconferences, face-to-face meetings, and one-to-one telephone calls or e-mail exchanges that impact Network and/or Study-specific functions. These records will be maintained by a designated party to document the content and frequency of communications, and to assess the effectiveness of communications.

To ensure completeness and continuity, action items from prior meetings should be reviewed at the start of each subsequent meeting and their status (i.e., ongoing, pending, completed) should be noted.

A study-specific Communication Plan that describes how each party involved with the management of a study (i.e., NINDS, CCC, DCC, PPI) will communicate, including details of membership for each study specific committee, frequency of meetings, and a detailed work scope of activities, will be developed for each NeuroNEXT study. Details for this plan will be captured in the study-specific manual of procedures (MOP) for each study.

2. SCOPE

This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 2016 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). The policies and procedures described in this SOP apply to the NeuroNEXT CCC and DCC within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT investigators, staff, subcontractors, or other entities associated with the NeuroNEXT Network who manage, oversee, and conduct research regulated by FDA and/or applicable review committees.

3. ROLES AND RESPONSIBILITIES

Each interested party (CCC, DCC, PPI, NINDS or other relevant group) is responsible for documenting any pertinent communication that it is responsible for managing (e.g. NeuroNEXT Executive Committee [NEC] meetings, Coordinator teleconferences, protocol working group [PWG] teleconferences, study team teleconferences), and for distributing this documentation to attendees for review.

Where applicable, it is the responsibility of the interested party sending written communication to confirm all parties have received, read and appropriately distributed the communication.

Each party in NeuroNEXT is responsible for ensuring appropriate other parties are apprised of changes or new relevant information to facilitate optimal functioning of the Network and study-specific activities.

The CCC, DCC, PPI and NINDS are responsible for developing a study specific Communication Plan for all NeuroNEXT studies.

Many of the other SOPs detail communication between interested parties for specific Network and project activities, such as study, medical and safety monitoring, protocol development, site and study start-up, etc.

4. APPLICABLE REGULATIONS AND GUIDELINES

21 CFR 312.50	General Responsibilities of Sponsors
ICH E6, 2.7	The Principles of ICH GCP
ICH E6, 5.1	Quality Assurance and Quality Control

5. REFERENCES TO OTHER APPLICABLE SOPS

NN RA 206 Medical Monitoring and Safety Monitoring
 NN PD 304 Clinical Protocol Finalization and Maintenance
 NN SS 403 Routine Monitoring Visits

6. ATTACHMENTS AND REFERENCES

NN PM 501 – A Document History

7. TERMS AND ABBREVIATIONS

The following terms and abbreviations are used in this document:

CCC Clinical Coordinating Center at Massachusetts General Hospital
 CSS Clinical Study Site
 DCC Data Coordinating Center at The University of Iowa
 FDA U.S. Food and Drug Administration
 GCP Good Clinical Practices
 ICH International Conference on Harmonisation
 NINDS National Institute of Neurological Disorders and Stroke
 PPI Protocol Principal Investigator

8. SPECIFIC PROCEDURES

A. Network Communication between NINDS, CCC and DCC

#	Who	Task	Attachment / References	Related SOP
1.	CCC PI / DCC PI	Communicate any desired changes or new relevant information to NINDS Program Directors in a timely fashion. Where applicable, this communication should be documented in writing (may include via email correspondence).		
2.	NINDS Program Directors	Communicate any Network changes or new relevant information to CCC PI and DCC PI in a timely fashion. Where applicable, this communication should be documented in writing.		

B. Network Communication between CCC/ DCC and CSS

#	Who	Task	Attachment / References	Related SOP
1	CCC	Email all CSSs montly, or as needed throughout the duration of the Network, with reminders and new information.		
2	CCC / DCC	Inform all appropriate parties of upcoming Network webinars, meetings and/or deadlines for requested information.		
3.	CCC / DCC	Provide meeting minutes and/or other appropriate documentation from applicable Network meetings and webinars to all CSSs.		

C. Study Specific Communication between CCC/ DCC and PPI

#	Who	Task	Attachment / References	Related SOP
1	CCC / DCC	Provide meeting minutes and/or other appropriate documentation from applicable study-specific meetings and webinars to PPI.		
2	CCC / DCC / PPI / NINDS	Develop study specific Communication Plan, to ensure all parties understand and accept their roles and responsibilities in management of the study.		

D. Study Specific Communication between CCC / DCC and CSS

#	Who	Task	Attachment / References	Related SOP
1	CCC / DCC	Provide meeting minutes and/or other appropriate documentation from applicable study-specific meetings and webinars to all CSSs.		

Certificate Of Completion

Envelope Id: C3E3131A905C4F418EE71F087E73C1F9 Status: Completed
Subject: Complete with DocuSign: NN PM 501 Communication v2.0.docx
Source Envelope:
Document Pages: 5 Signatures: 6 Envelope Originator:
Certificate Pages: 6 Initials: 0 Tania Leeder
AutoNav: Enabled TLEEDER@PARTNERS.ORG
Envelopeld Stamping: Disabled IP Address: 73.123.188.5
Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Record Tracking

Status: Original Holder: Tania Leeder Location: DocuSign
2/15/2023 8:23:33 AM TLEEDER@PARTNERS.ORG

Signer Events

Christopher Coffey Signature Timestamp
christopher-coffey@uiowa.edu Christopher Coffey Sent: 2/15/2023 8:25:50 AM
Security Level: Email, Account Authentication Viewed: 2/15/2023 11:19:37 AM
(Required), Login with SSO Signed: 2/15/2023 11:19:48 AM
Signature Adoption: Pre-selected Style
Signature ID:
C68AC8DD-8033-4CF9-82AE-D1200765F147
Using IP Address: 128.255.113.139
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/15/2023 11:19:37 AM
ID: ac080dcc-d05c-44a5-bc31-904a6cde8605

DIXIE ECKLUND
dixie-ecklund@uiowa.edu
Security Level: Email, Account Authentication
(Required), Login with SSO

DocuSigned by DIXIE ECKLUND
I approve this document
15-Feb-2023 | 11:05:15 AM PST
7006AF622EFC40B6A067A08EC02591B6

Sent: 2/15/2023 8:25:51 AM
Viewed: 2/15/2023 2:01:02 PM
Signed: 2/15/2023 2:05:18 PM

Signature Adoption: Drawn on Device
Signature ID:
7006AF62-2EFC-40B6-A067-A08EC02591B6
Using IP Address: 128.255.112.230

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/15/2023 2:01:02 PM
ID: 3aba6700-6393-433d-b761-57acc4f610ad

Signer Events	Signature	Timestamp
---------------	-----------	-----------

Joan Ohayon
ohayonj@ninds.nih.gov
Security Level: Email, Account Authentication (Required)

Joan Ohayon

Sent: 2/15/2023 8:25:52 AM
Viewed: 2/15/2023 12:03:46 PM
Signed: 2/15/2023 12:04:09 PM

Signature Adoption: Pre-selected Style
Signature ID:
72C6AAFD-8CC4-4855-82AC-A0700072901A
Using IP Address: 156.40.137.188

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/13/2023 2:03:22 PM
ID: 385a0a53-0f0c-4395-88f6-d5700c36e050

Marianne Chase
MCHASE@mgh.harvard.edu
Sr Director, Clinical Trial Operations
Insight OBO The Massachusetts General Hospital
Security Level: Email, Account Authentication (Required)

Marianne Chase


Sent: 2/15/2023 8:25:51 AM
Viewed: 2/15/2023 8:48:38 PM
Signed: 2/15/2023 8:49:12 PM

Signature Adoption: Pre-selected Style
Signature ID:
58FE690F-6BCA-4F23-90E3-DA15BCE3F578
Using IP Address: 73.114.253.109

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

Merit Cudkowicz
cudkowicz.merit@mgh.harvard.edu
Chief of Neurology
Security Level: Email, Account Authentication (Required), Logged in


DocuSigned by Merit Cudkowicz

I approve this document
17-Feb-2023 | 9:36:02 AM EST
9F8FE4180E504C6AB0A67B835E80C644

Sent: 2/15/2023 8:25:52 AM
Viewed: 2/17/2023 9:35:53 AM
Signed: 2/17/2023 9:36:05 AM

Signature Adoption: Pre-selected Style
Signature ID:
9F8FE418-0E50-4C6A-B0A6-7B835E80C644
Using IP Address: 68.239.56.73

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/17/2023 9:35:53 AM
ID: 7721785f-d161-4432-9d33-0bc16442d92f

Signer Events	Signature	Timestamp
Stacey Grabert sgrabert@mgh.harvard.edu Director QA Stacey Grabert Security Level: Email, Account Authentication (Required)	 Signature Adoption: Pre-selected Style Signature ID: 60CC52B0-747A-44E6-B220-8D8D880698C0 Using IP Address: 132.183.56.49 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/15/2023 8:25:52 AM Viewed: 2/22/2023 11:24:03 AM Signed: 2/22/2023 11:24:18 AM
Electronic Record and Signature Disclosure: Accepted: 7/20/2020 8:50:14 AM ID: 5ebadf74-e399-40fd-be82-9c7ca902061b		
In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	2/15/2023 8:25:53 AM
Certified Delivered	Security Checked	2/22/2023 11:24:03 AM
Signing Complete	Security Checked	2/22/2023 11:24:18 AM
Completed	Security Checked	2/22/2023 11:24:18 AM
Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Insight OBO The Massachusetts General Hospital (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Insight OBO The Massachusetts General Hospital:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: jhenrique@mgh.harvard.edu

To advise Insight OBO The Massachusetts General Hospital of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at jhenrique@mgh.harvard.edu and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Insight OBO The Massachusetts General Hospital

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Insight OBO The Massachusetts General Hospital

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Insight OBO The Massachusetts General Hospital as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Insight OBO The Massachusetts General Hospital during the course of your relationship with Insight OBO The Massachusetts General Hospital.